One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2021-148668
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 2 |
Affiliation: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Oregon Health & Science University, Incyte (United States), University of Southern California, Emory University, Icahn School of Medicine at Mount Sinai, Washington University in St. Louis, Roswell Park Cancer Institute, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, University of California, Los Angeles, University of Kansas Cancer Center, Montefiore Medical CenterSubgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
